Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Tempus AI | Teradyne | Oracle | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." | narrow Real but bounded: the FY2025 10-K reports gross profit at 58.2% of total revenues, a level it records as a decrease - 'Gross profit as a percent of total revenues decreased by 0.3 points, primarily due to product mix' from 58.5% in 2024 - while a shared IG-XL test-program environment spans the FLEX and J750 families. Against that, the filing's own risk-factor heading is 'We are subject to intense competition' and it concedes that 'Some of our competitors have introduced or announced new products with certain performance characteristics that may be considered equal or superior to those we currently offer,' adding that it faces competition 'from emerging Asian companies and internal development at several of our customers.' | wide Oracle's FY2026 10-K (fiscal year ended May 31, 2026) describes an installed base in which "substantially all customers opt to purchase software support contracts when they purchase an Oracle software license"; that entrenchment shows up externally as the #1 DB-Engines database ranking (August 2026, first of 435 systems) and $638B of contracted Remaining Performance Obligations at Q4 FY2026 (press release, June 10, 2026) — a durable, multi-decade lock on mission-critical enterprise data layers. |
| Moat type | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. | switching costs The 10-K's Products section grounds the stickiness in test-program and capital reuse rather than in protected IP: the FLEX Test Platform runs 'The IG-XL™ software operating system which provides fast program development, including instant conversion from single to multi-site test', the J750 'shares the IG-XL software environment with the family of FLEX Test Platform systems,' and its instruments are 'coupled with a universal slot test head design that allows easy test system reconfiguration to address changing test needs.' The filing credits that versatility with making FLEX 'a widely used test solution at OSATs... allowing OSATs to leverage their capital investments.' The same 10-K expressly disclaims an IP-based moat: 'We do not believe that any single piece of intellectual property or proprietary rights is essential to our business.' | switching costs The core moat is the cost of moving mission-critical databases and back-office suites: the FY2026 10-K notes substantially all license customers attach support contracts and that Oracle's Multicloud Database offerings run Oracle AI Database inside other hyperscalers' clouds — monetizing the installed base even when the customer's infrastructure leaves; the KLAS 2026 EHR report shows the same dynamic in health IT, where roughly a third of Oracle Health customers want to leave but feel unable to do so. |
| Leadership | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. | co leader The 10-K opens by calling Teradyne 'a leading global provider of automated test equipment and robotics solutions' - a leading provider, not the leader - and its Competition section names Semiconductor Test rivals non-exhaustively: competitors 'include, among others, Advantest Corporation, SPEA S.p.A., and Cohu, Inc.' It discloses no share figure and warns that competitors' announced products 'may be considered equal or superior to those we currently offer,' which reads as shared leadership rather than a clear lead. | co leader Split by line: clear leader in database (DB-Engines August 2026 ranks Oracle #1 and Oracle-owned MySQL #2 of 435 systems); one of the largest enterprise-application vendors ($15.9B FY2026 SaaS revenue, competing with SAP, Salesforce, Workday and Microsoft per the FY2026 10-K); but in cloud infrastructure a ~4%-share fast-growing challenger behind Amazon (28%), Microsoft (20%) and Google (15%) per Synergy Q2 2026 data (The Register, 2026-08-01), and #2 in US acute-care EHR behind Epic (KLAS 2026). |
| Pricing power | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). | moderate Gross profit was 58.2% of total revenues in 2025 against 58.5% in 2024, and the 10-K attributes the 0.3-point decline to product mix; product gross margin fell 0.8 points to 57.3%. The risk factor 'Our operating results are likely to fluctuate significantly' lists 'competitive pressures on selling prices' among factors that 'could impact future operations,' and the same list cites the tendency of customers to 'wait until late in a quarter to commit to purchase... or the hope of obtaining more favorable pricing from a competitor seeking the business' - margin is defended, not expanded. | moderate Strong in the installed base — the FY2026 10-K states substantially all license customers purchase support contracts, a recurring stream customers rarely drop — but the same 10-K lists "total cost of ownership" first among key competitive factors and describes intense competition across every segment; AI-infrastructure deals are won against hyperscalers and neoclouds, and Q4 FY2026 SaaS grew a moderate 10% versus 93% for IaaS (press release, June 10, 2026). |
| Summary | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. | Teradyne sells the test step that sits between fabrication and shipment, and its hold on customers comes from platform continuity rather than patents. The FY2025 10-K describes one IG-XL software environment shared across the FLEX and J750 test families and a universal slot test head that lets a customer reconfigure a system to address changing test needs, which the filing credits with making FLEX widely used at OSATs because it lets them leverage their capital investments. The margin that continuity sits on is high but not rising: gross profit was 58.2% of revenue in 2025, which the filing records as a 0.3-point decrease from 2024 on product mix, with product margin down 0.8 points to 57.3% and service margin up 2.9 points to 62.9% - and the filing attributes that service gain to the May 2024 sale of the DIS business, not to the platform. It is a narrow moat, not a wide one: the filing names Advantest, SPEA and Cohu 'among others' in Semiconductor Test, warns of internal development at several customers, states that rival products may be 'equal or superior,' and discloses that the five largest direct customers rose to 44% of consolidated revenue in 2025 from 36% in 2024 - buyer power that caps how much of the platform advantage converts to price. | Oracle pairs the deepest switching-cost franchise in enterprise software — the #1-ranked database (DB-Engines, August 2026) plus Fusion/NetSuite back-office suites, with support attach near-universal per the FY2026 10-K — with a late but explosive push into AI cloud infrastructure: Q4 FY2026 IaaS revenue grew 93% to $5.8B and RPO reached $638B (up 363% YoY), mostly large-scale AI contracts (press release, June 10, 2026). The two reinforce each other via multicloud — Oracle Multicloud AI Database grew 404% in Q4 running inside rival clouds. The offsets: in cloud infrastructure Oracle is still a ~4%-share challenger behind AWS/Microsoft/Google (Synergy Q2 2026 data via The Register), the AI buildout drove FY2026 free cash flow to negative $23.7B, and the Cerner-based Oracle Health business has lost US hospital share for three straight years (KLAS 2026). |
| Chain position | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. | Back-end capital equipment: its testers sit between fabrication and shipment, and the 10-K states that AI related customer demand drove the majority of revenue in the second half of 2025, with Semiconductor Test at 79% of consolidated revenue. | Supply-chain role in AI: OCI sells GPU compute for AI training and inference — the Q4 FY2026 press release attributes most of the $85B sequential RPO increase to large-scale AI contracts (some with customer-prepaid or customer-supplied GPUs totaling $75B) and guides FY2027 total revenue to $90B — making Oracle a primary capacity supplier to AI model builders. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm bullish Editorial prior, not backtested. |